Positive data from trials of MedImmune's FluMist

1 April 2007

US drugmaker MedImmune says that data from three key studies of its nasal influenza vaccine FluMist (live influenza vaccine) demonstrate both the drug's efficacy, and a potentially effective model for rapid, large-scale vaccination.

FluMist cuts number of flu cases 55%

The efficacy findings, which formed the basis of the firm's presentation at the National Association of Pediatric Nurse Practitioners 28th annual conference, held in Buena Vista, Florida, showed that vaccinated children between the age of six months and five years, experienced 55% fewer cases of flu than a similar cohort treated with an intravenous influenza vaccine. In addition, the results, which were originally published in the New England Journal of Medicine, confirmed that the vaccine was effective against both matched and mistmatched strains of the influenza virus.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >

Today's issue

Company Spotlight

Ironwood is a US-based biotech advancing a pipeline of medicines in multiple areas of significant unmet need, including irritable bowel syndrome with constipation ((IBS-C)/chronic idiopathic constipation (CIC), vascular and fibrotic diseases, and refractory gastroesophageal reflux disease, among others.